SRR6013570
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.570
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- PROTEIN_SECRETION+0.430
- ANGIOGENESIS+0.400
- MTORC1_SIGNALING+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.310
- TGF_BETA_SIGNALING+0.230
- UV_RESPONSE_DN+0.230
Top 10 suppressed
- MYOGENESIS-0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- XENOBIOTIC_METABOLISM-0.150
- BILE_ACID_METABOLISM-0.140
- ESTROGEN_RESPONSE_EARLY-0.140
- CHOLESTEROL_HOMEOSTASIS-0.110
- KRAS_SIGNALING_DN-0.110
- HEDGEHOG_SIGNALING-0.090
- UV_RESPONSE_UP-0.090
- ESTROGEN_RESPONSE_LATE-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934935 | — | — | 0.819 |
| 2 | ERR2598169 | fetal | fetal | 0.817 |
| 3 | SRR934813 | — | — | 0.815 |
| 4 | BS_84XCR9GG | high-grade glioma | — | 0.810 |
| 5 | MDT-AP-3317 | Med | Medulloblastoma | 0.807 |
| 6 | 8ACC0F29-A39E-4C1C-A04C-ED6E5FA80C24 | — | — | 0.806 |
| 7 | TCGA-64-5775-01A-01R-1628-07 | — | cohortA1 | 0.802 |
| 8 | C3N-00211 | — | cohortSQ1 | 0.798 |
| 9 | SRR934902 | — | — | 0.797 |
| 10 | ERR2208969 | — | — | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |